Scott Lunin is a partner in the Corporate Practice Group. His practice focuses on advising domestic and foreign issuers and investment banks in capital market transactions, corporate governance and public company counseling, with a particular emphasis on the life sciences and technology industries. Mr. Lunin has successfully represented clients in a wide range of complex capital markets transactions, including initial public offerings, follow-on equity offerings, PIPEs and senior debt offerings.

Mr. Lunin regularly advises life sciences companies on financing transactions, SEC reporting and disclosure requirements, stock exchange requirements and corporate governance issues. He also advises emerging companies on a variety of matters, including venture capital financings.

In recent years, Mr. Lunin has advised Schrödinger, Dyne Therapeutics, Decibel Therapeutics, Nabriva Therapeutics and Summit Therapeutics on their initial public offerings. He has also advised investment banks on the initial public offerings of Theseus Pharmaceuticals, TCR² Therapeutics and Entasis Therapeutics. 

Before joining WilmerHale, Mr. Lunin was a senior attorney at IBM where he advised on a variety of corporate and securities matters. Prior to attending law school, Mr. Lunin served as an intelligence officer with the Defense Intelligence Agency.

Mr. Lunin serves on Law360's Capital Markets Advisory Board.